Are there any regulatory milestones, FDA meetings, or other key dates scheduled in the near term?
Answer
Based on the press‑release you provided, the only near‑term corporate events that Cellectar Biosciences, Inc. (NASDAQ: CLRB) has announced are:
| Date (2025) | Event | Description |
|---|---|---|
| August 14 | Second‑quarter earnings release & corporate update | The company will publish its Q2 2025 financial results (for the quarter ended June 30, 2025) and hold a conference call at 8:30 a.m. Eastern Time. |
Regulatory or FDA‑related milestones
The release does not mention any upcoming regulatory filings, FDA advisory committee meetings, submission deadlines (e.g., IND, NDA, BLA), or other key dates such as:
- Planned clinical‑trial milestones (e.g., enrollment completions, data‑readout dates)
- FDA meetings (e.g., Type B or Type C meetings, PDUFA dates)
- Regulatory decision dates (e.g., expected action on a pending submission)
Therefore, no regulatory or FDA milestones are disclosed in this particular announcement. The only scheduled activity is the earnings release and conference call on Thursday, August 14, 2025.
What to Do Next
- Monitor future communications: Cellectar typically announces regulatory timelines in separate press releases, SEC filings (e.g., Form 8‑K, 10‑Q), or updates on its investor‑relations website. Keep an eye on those sources for any upcoming FDA interactions.
- Check the company’s investor‑relations calendar: The “Events & Presentations” section on Cellectar’s IR site often lists upcoming conferences, trial updates, and regulatory meetings.
- Set alerts for SEC filings: If a new IND, NDA, or other regulatory submission is planned, the company is required to file a Form 8‑K or 10‑Q, which will be posted on the SEC’s EDGAR system.
If you need a deeper dive into Cellectar’s pipeline‑specific regulatory timelines (e.g., expected data‑readouts for its lead candidates), you would need to consult additional disclosures beyond the August 7, 2025 press release.